Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. Achaogen
AKAO

Buy Achaogen (AKAO) Stock

AKAO
See AKAO stock price and Buy/Sell Achaogen with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
AKAO

Achaogen (AKAO)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Achaogen (AKAO)

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infectio...Read more
Market Cap
$1.6M
1 Year High
$0.05
Volume
1 Year Low
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch AKAO stock

Achaogen Stock Rating

What analysts recommend for AKAO stock, on a scale from 1(buy) to 5(sell).
Hold3 / 5
BuyHoldSell

Achaogen Stock Earnings

The value each AKAO share was expected to gain vs. the value that each AKAO share actually gained.
Expected
Actual

Achaogen Stock News

Frequently Asked Questions (FAQ)

As of Sep 26, 2022, the market cap for Achaogen stock is $1.6M

The 52-week high for Achaogen stock is $0.05. The current Achaogen stock price $0 is 100.00% below its 52-week high

No, the Achaogen stock does not pay dividends to its shareholders

The target price for Achaogen stock is $2 based on the average of what a group of analyst think Achaogen stock could be worth at a future date. This is not a prediction by Public.com

Buy Achaogen (AKAO) Stock

AKAO
See AKAO stock price and Buy/Sell Achaogen with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch AKAO stock
  • paix avatar
  • Kenson avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.